Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Phesgo (Pertuzumab Trastuzumab Injection 1200+600)
Phesgo is an innovative fixed-dose combination of Pertuzumab (Perjeta) and Trastuzumab (Herceptin), along with hyaluronidase, formulated for subcutaneous (under the skin) injection. It is specifically designed for the treatment of early and metastatic HER2-positive breast cancer.
Uses of Phesgo (Pertuzumab Trastuzumab Injection 1200+600)
Phesgo is used for:
Treatment of HER2-positive breast cancer, both in early and metastatic stages, in combination with intravenous chemotherapy.
Benefits of Phesgo (Pertuzumab Trastuzumab Injection 1200+600)
Provides a convenient and faster administration option compared to traditional intravenous methods, with injections completed in minutes instead of hours.
Offers dual blockade of HER2 signalling pathways, potentially enhancing treatment efficacy and patient outcomes.
Allows flexibility in treatment settings, enabling administration in both healthcare facilities and home settings.
Mechanism of Action of Phesgo (Pertuzumab Trastuzumab Injection 1200+600)
Phesgo combines Pertuzumab and Trastuzumab, which bind to distinct sites on the HER2 receptor, resulting in a synergistic blockade of HER2 signalling pathways. This dual inhibition impedes tumour cell growth and survival. The addition of hyaluronidase facilitates rapid dispersion and absorption of the medication under the skin, optimizing therapeutic delivery.